Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.

G G Hanna1, L Murray2, R Patel3

  • 1Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|October 17, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors.

ESMO open·2026
Same author

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

ESMO open·2026
Same author

Radiotherapy Plan Quality Assurance in the ABC-07 Trial of Stereotactic Body Radiotherapy for Locally Advanced Biliary Tract Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Establishing a National SABR Service: A Model for Safe and Effective Clinical Implementation.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Reconsidering Governance Models to Strengthen Rural Healthcare.

Journal of bioethical inquiry·2025
Same author

Liver Metastases Treated With Magnetic Resonance Imaging Guided Stereotactic Body Radiation Therapy: Outcomes of Tolerability, Acute Toxicity, and Quality of Life From the MOMENTUM Study.

Practical radiation oncology·2025
Same journal

Research Trends in Physical Activity and Breast Cancer: A 25-Year Bibliometric Analysis (2000-2025).

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Concordance Between Planned and Delivered treatment for Head and Neck Cancer Patients Treated With Curative Intent: A Real-World Comparison of Under 70-year-olds With 70-year-olds and Over.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

A Novel Technique for Pain Management to Deliver a Course of Palliative Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Broad-Spectrum Antibiotics are Associated with worse Survival After Radical Treatment for Glioblastoma Multiforme: A Multicentre Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Exploring the Need for Plan Adaptation in Robustly Optimised Head and Neck Intensity Modulated Proton Therapy: A Dosimetric Perspective From Initial Institutional Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Lifting the Lid on Best Practice in a Case of Oligometastatic Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
See all related articles
This summary is machine-generated.

Six UK studies on stereotactic ablative radiotherapy (SABR) for oligometastatic disease have established consensus organ at risk dose constraints. This unified approach aims to standardize SABR implementation and enable robust toxicity comparisons internationally.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Physics

Background:

  • Stereotactic ablative radiotherapy (SABR) is increasingly used for oligometastatic disease.
  • Several UK-based clinical trials investigating SABR are currently active.
  • Standardized organ at risk (OAR) dose constraints are crucial for safe and comparable SABR implementation.

Purpose of the Study:

  • To develop a consensus document on OAR dose constraints for SABR studies in the UK.
  • To update existing dose constraints using data from current UK SABR trials.
  • To facilitate standardized SABR implementation and facilitate international toxicity comparisons.

Main Methods:

  • Collaboration among members of multiple SABR trial management groups.
  • Review and update of existing OAR dose constraints.
Keywords:
ConstraintsOARSABRSBRTnormal tissuestereotactic radiotherapy

Related Experiment Videos

  • Utilizing data from six ongoing UK SABR studies.

    • Main Results:

    • A consensus document on appropriate OAR dose constraints for SABR has been generated.
    • Updated dose constraints incorporate data from current UK SABR studies.
    • The consensus provides a unified approach for SABR implementation.

    Conclusions:

    • The developed consensus document will promote standardized SABR practices across the UK.
    • This unified approach is expected to improve the comparability of toxicity data between SABR studies, both nationally and internationally.